Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | CDK1 | P06493 | 10/20 | 0.38 |
| ▸ | CDK2 | P24941 | 10/20 | 0.38 |
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447995 | 0.88 | IGF1R (0.47) | HDAC3HDAC1HDAC2HDAC6CDK2 | |
| SCHEMBL3449668 | 0.87 | GRM5 (0.50) | HDAC3HDAC1HDAC2HDAC6CDK1 | |
| SCHEMBL3449221 | 0.82 | KDR (0.42) | CDK1CDK2KDRIGF1RSYK | |
| SCHEMBL3348225 | 0.80 | IGF1R (0.55) | HDAC3HDAC1HDAC2HDAC6CDK2 | |
| SCHEMBL3350947 | 0.79 | MAPK1 (0.51) | IGF1RSYK | |
| SCHEMBL4584347 | 0.77 | IGF1R (0.48) | CDK1CDK2KDRIGF1RSYK | |
| SCHEMBL13420174 | 0.75 | SYK (0.54) | CDK2KDRIGF1RSYKCDK4 | |
| SCHEMBL3448970 | 0.75 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC6CDK2 | |
| SCHEMBL3450104 | 0.75 | CDK1 (0.47) | CDK1CDK2KDR | |
| SCHEMBL3448567 | 0.74 | HDAC3 (0.46) | HDAC3HDAC1HDAC2HDAC6CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | HDAC3 1200/4885HDAC1 1109/4885HDAC2 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.